Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
Condition: Herpes Zoster Interventions: Biological: Low dose Recombinant Herpes Zoster Vaccine (CHO cells); Biological: High dose Recombinant Herpes Zoster Vaccine (CHO cells); Biological: Positive control; Biological: Placebo Sponsors: MAXVAX Biotechnology Limited Liability Company; Henan Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Herpes | Research | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine